Applying Emerging Antiretroviral Data to Clinical Practice: A Case-Based Program (On-Demand)

Needs Assessment

Rapid advances in HIV disease management require the ongoing attention of clinicians involved in direct patient care. Clinicians must continually adapt to evolving data on ART, including new agents, emerging treatment strategies, and important findings presented at major scientific meetings such as CROI. As treatment options expand, providers may face challenges in selecting and optimizing ART regimens, integrating new therapies into clinical practice, and making informed treatment decisions for individuals who are treatment-naive or treatment-experienced. This course will address the clinical implications of this new data in HIV and treatment. Information will be presented through a mix of didactic presentations, clinically relevant cases, and interactive discussions led by an expert faculty of HIV clinicians and researchers.

Learning Objectives

After participating in the activity, learners will be able to:

• Implement the latest recommendations for initiating and changing ART in different clinical circumstances
• List drugs for selecting initial ART therapy, including the role of newly approved in clinical practice
• Apply considerations for hepatitis B in the era of 2-drug ART, including screening, interpreting complex serologies, and vaccination
• Evaluate strategies for simplifying ART in treatment-experienced individuals and those with HIV drug resistance
• Recognize clinical considerations for ART in advanced HIV disease, including use in the setting of opportunistic infections and comorbid conditions

Preliminary Topics

• Initial ART: integrating newly approved agents into clinical practice
• 2-drug ART: Considerations for Hepatitis B: screening, interpreting complex serologies, vaccination
• Simplifying ART in treatment-experienced individuals and those with HIV drug resistance
• ART and Advanced HIV disease: managing ART in the setting of opportunistic infections and cormorbid conditions

Conflicts of Interest

In the interest of maintaining the independence of its continuing medical education (CME) activities, the International Antiviral Society–USA (IAS–USA) requires all persons with control of educational content (eg, faculty, Scientific Leadership Board, Governance Board, and program planner) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they have had within the past 24 months. Any real or apparent conflicts of interest of those parties are resolved and mitigated prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in IAS–USA CME activities. 

The Accreditation Council for Continuing Medical Education (ACCME) defines ineligible companies as “those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.”

IAS–USA has identified and mitigated ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Information about financial relationships with ineligible companies for the presenter and planners/reviewers is below and in the slides prior to the presentation of educational content.

Registration

Who Should Attend

This course is designed for physicians who are actively involved in the medical care of people with HIV infection and:

• Have a solid, working knowledge of HIV disease management
• Provide comprehensive or specialty care for patients with HIV infection

This activity is also relevant to nurse practitioners, registered nurses, physician assistants, registered pharmacists, and other health professionals.

Please note: if you have already participated in the live course and have received CME credits, you will not receive additional credits from this activity.